<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004081</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067292</org_study_id>
    <secondary_id>BIH-99-1286</secondary_id>
    <secondary_id>NCI-V99-1565</secondary_id>
    <nct_id>NCT00004081</nct_id>
  </id_info>
  <brief_title>Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Trial of Weekly, Low-Dose Docetaxel (Taxotere) in Patients With Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Serous Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating women who have&#xD;
      ovarian epithelial cancer or primary peritoneal cancer that has not responded to previous&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the activity of docetaxel in women with platinum resistant, refractory ovarian&#xD;
           epithelial or primary peritoneal serous cancer.&#xD;
&#xD;
      OUTLINE: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving complete response (CR) receive a minimum of 6 courses of therapy, including 2&#xD;
      courses beyond CR.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial or primary peritoneal serous cancer that&#xD;
             is resistant to platinum therapy&#xD;
&#xD;
          -  Platinum resistance as defined by one of the following:&#xD;
&#xD;
               -  Relapse within 6 months of platinum based chemotherapy&#xD;
&#xD;
               -  Residual disease after completion of platinum based chemotherapy&#xD;
&#xD;
               -  Disease progression while receiving platinum based chemotherapy&#xD;
&#xD;
               -  Marker only relapse (CA-125 elevation) and measurable disease&#xD;
&#xD;
          -  Bidimensionally measurable disease on exam or CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT or SGOT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Acceptable cardiac exam&#xD;
&#xD;
          -  No active cardiac ischemia&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Acceptable pulmonary exam&#xD;
&#xD;
          -  No active pulmonary infection or compromise&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No severe peripheral neuropathy (grade 2 or greater)&#xD;
&#xD;
          -  No other significant psychiatric or medical conditions that would interfere with&#xD;
             compliance&#xD;
&#xD;
          -  No other malignancies within the past 3 years, except:&#xD;
&#xD;
               -  Limited basal or squamous cell skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior cytokine therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for ovarian epithelial or peritoneal serous&#xD;
             cancer&#xD;
&#xD;
          -  Prior paclitaxel allowed&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
          -  At least 3 years since prior chemotherapy for other disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen A. Cannistra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec;95(3):624-31. doi: 10.1016/j.ygyno.2004.08.028.</citation>
    <PMID>15581974</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Stephen Cannistra, MD</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

